Your message has been sent sucessfully
20
Years19800
Patients has been treated31
Patent27000
Transfusion of cell preparations102
Tissue engineering operations of the human spinal cord
Clinical Hospital "NeuroVita" was open in May 2002 in Moscow, Russia.
It is the first private hospital of 35 beds that specializes in the use of the interventional (low invasive) medical technologies of bioengineering and cell therapy for the complex therapy of cancer including neurooncology, therapy of neural diseases as well as for the restorative therapy and rehabilitation in the cases of oncological and neurological diseases. The first oncological, neurological and neurosurgical patients were admitted to the hospital September 2, 2002 and since, the hospital successfully provides the specialized medical service to the population of Russia, as well as to the patients from abroad.
For over 20 years our clinical hospital admits neurological and oncological patients from all parts of the world for diagnostics and therapy. In most cases these patients cannot be helped by conventional methods of treatment and rehabilitation. All these years we have been developing individually tailored innovative medical biotechnologies and novel protocols in the area of molecular (genome and post-genome) and regenerative medicine, many of which are unparalleled in the world. Such technologies as ultra-early post-genome diagnostics of cancer and neurodegenerative diseases with artificial intelligence, remote controlled multi-wave radioneuroengineering of the brain, tissue engineering of the spinal cord, anti-cancer molecularly targeted cell preparations, biological highly technological cell-based pharmaceuticals, neurodegenerative biomedical cell products are patented in the Russian Federation and abroad and serve our business card in Russia and in the world. Back in 2005 we officially registered the cell technologies of the injured brain and spinal cord in the Roszdravnadzor; these technologies have acquired the status of medical technologies and approved for clinical application in Russia. Over 10 000 patients received the therapy of severe consequences of neural traumas and over 25000 injections of cell preparations have been administered to enhance the efficiency of rehabilitation almost in 61%. Our recent advance and an academic breakthrough are ex vivo gene therapy of orphan (rare) hereditary neural and neurodegenerative diseases that has been developed in cooperation with Novosibirsk geneticists and Moscow molecular biologist.
Chief Executive Officer of AO NeuroVita Clinical Hospital holder of second-level doctorate degree in medicine, Professor Andrey S. Bryukhovetskiy, Neurologist of top category, Healthcare organization expert 40 years of clinical and research experience Vice-president of “International Association of Neurorestoratology “
We are ready to search for the way out from the most complicated health situations that you face. The medical biotechnology to extend life span of the human for 10-15 years has been tested in the experiment and the human clinical trials are planned to start this year. Our experts develop individually tailored course of highly technological treatment of your disorder for you relying on the clinical and molecular-biological values of your organism and on your wishes in a contemporary hospital of European level.
Your message has been sent sucessfully